CD82 antibody (C-Term)
-
- Target See all CD82 Antibodies
- CD82
-
Binding Specificity
- C-Term
-
Reactivity
- Human, Mouse, Rat
-
Host
- Rabbit
-
Clonality
- Polyclonal
-
Conjugate
- This CD82 antibody is un-conjugated
-
Application
- Western Blotting (WB), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p)), Enzyme Immunoassay (EIA)
- Specificity
- This antibody detects CD82 at C-term.
- Cross-Reactivity (Details)
- Species reactivity (tested):Human, Mouse
- Purification
- Peptide affinity chromatography
- Immunogen
- KAI1 antibody was raised against a 15 amino acid peptide from near the carboxy terminus of human KAI1.
- Isotype
- IgG
- Top Product
- Discover our top product CD82 Primary Antibody
-
-
- Application Notes
-
ELISA. Western blot: 0.5 - 1 μg/mL. Immunohistochemistry on paraffin sections.
Other applications not tested.
Optimal dilutions are dependent on conditions and should be determined by the user. - Restrictions
- For Research Use only
-
- Buffer
- PBS containing 0.02 % sodium azide
- Preservative
- Sodium azide
- Precaution of Use
- This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
- Handling Advice
- Avoid repeated freezing and thawing.
- Storage
- 4 °C/-20 °C
- Storage Comment
- Store at 2 - 8 °C for up to one month or (in aliquots) at -20 °C for longer.
-
- Target
- CD82
- Alternative Name
- CD82 (CD82 Products)
- Synonyms
- AA682076 antibody, AL023070 antibody, C33 antibody, IA4 antibody, Kai1 antibody, Tspan27 antibody, 4F9 antibody, GR15 antibody, KAI1 antibody, R2 antibody, SAR2 antibody, ST6 antibody, TSPAN27 antibody, CD82 antigen antibody, CD82 molecule antibody, Cd82 molecule antibody, Cd82 antibody, CD82 antibody
- Background
- KAI1 was initially identified from a T-cell activation study as a four-transmembrane protein that plays an accessory role in T-cell activation, and was later determined to act as a cancer metastasis suppressor gene. This protein is ubiquitously expressed at moderate to high levels in most tissues, but its expression is downregulated during tumor progression. The loss of KAI1 and p53 is associated with poor survival for prostate and other cancer patients. Recently, KAI1 was found to interact with DARC, the Duffy antigen for chemokines using a yeast two hybrid screen. It is thought that tumor cells dislodged from the primary tumor and expressing KAI1 interact with DARC proteins expressed on vascular cells, transmitting a senescent signal to the tumor cells, while tumor cells that have lost KAI1 expression can proliferate and potentially give rise to metastases. At least two isoforms of KAI1 are known to exist.Synonyms: C33 antigen, IA4, Inducible membrane protein R2, KAI1, Kangai-1, Metastasis suppressor Kangai-1, SAR2, ST6, Suppressor of tumorigenicity protein 6, TSPAN27, Tetraspanin-27
- Gene ID
- 3732
- NCBI Accession
- NP_002222
- UniProt
- P27701
- Pathways
- p53 Signaling
-